About Us

Kunming Biomed International (KBI) is a world leading CRO providing preclinical research services that specialized in nonhuman primates (NHPs).  Led by an experienced international team, KBI has collaborated with over 18 large pharmas using translational NHP models for pharmacological efficacy and safety evaluations, including NASH/fibrosis, diabetes and diabetic complications (nephropathy, Ophthalmopathy), and cardiovascular diseases (dyslipidemia, heart failure), etc.  KBI has state-of-the-art AAALAC accredited animal research facilities, and extensive colonies (>3000) of healthy and diseased models.

Team Members

Although members of the KBI team are not active during the NASH Summit, please take the opportunity to reach out to the below contacts with any questions that you may have:


Chief Executive Officer

Chief Technology Officer